Virtual Library
Start Your Search
R. Li
Author of
-
+
P3.07 - Poster Session with Presenters Present (ID 493)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Regional Aspects/Health Policy/Public Health
- Presentations: 1
- Moderators:
- Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P3.07-022 - Progress against Non-Small-Cell Lung Cancer (NSCLC) Compared to Other Solid Tumors (ID 5482)
14:30 - 15:45 | Author(s): R. Li
- Abstract
Background:
The recent genomics revolution has provided unprecedented insights into the molecular complexity of cancer cells. Even within the same individual, tumor cells adapt to their environment, evade treatment attempts, and develop resistance against initially efficacious treatments. NSCLC has been shown to be among the most complex cancer types. Multiple approaches, in combination, hold promise to gain ground against this hard-to-treat disease. At the same time, successful preventive efforts can substantially reduce disease burden by decreasing the incidence of the disease. Depending on an individual’s preferences, treatment goals may vary from emphasis of quality of life to seeking a lasting cure even at the cost of substantial side effects. This complex picture of etiology, treatment strategies, and patient preferences must be reflected in any assessment of progress against the disease.
Methods:
We previously introduced the PACE Continuous Innovation Indicators™ (PACE CII) to measure progress against 12 different solid tumor types (https://pacenetworkusa.com/continuousinnovation). In the present work, we expanded the functionality of the tool to include an interactive user interface based on the Shiny (R online) platform that allows for custom-weighted analyses. We used this tool to compare progress against NSCLC with other tumor types when different weights are assigned to different treatment contexts and goals.
Results:
When assigning the largest weights to advanced and/or metastatic disease, NSCLC has seen the most progress (i.e. E-Score increase) over the past 30 years among the 12 common tumor types included in the tool. When focusing on progress against early stage disease and in the adjuvant context, however, NSCLC loses its top position to breast cancer. In both analyses, evidence for treatments that increase survival begins to accumulate in the 1990s and accelerates in the early 2000s, partly driven by the advent of targeted treatments.
Conclusion:
The global fight against cancer is a very substantial societal investment, and being able to track progress in specific domains will likely be critical for focusing this endeavor. To account for the complexity of the disease, progress cannot be summarized by a single metric. We here show how the PACE CII can help obtain a multi-faceted, complex picture of progress across the entire spectrum of tumor complexity and based on varying patient values. We encourage the field to use this public database to conduct additional analyses based on individual interests and preferences.
